Dirozalkib

Dirozalkib
Identifiers
  • 5-Chloro-2-N-(6-methyl-5-piperidin-4-yl-2,3-dihydro-1,4-benzodioxin-8-yl)-4-N-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine
CAS Number
PubChem CID
IUPHAR/BPS
UNII
Chemical and physical data
FormulaC27H32ClN5O4S
Molar mass558.09 g·mol−1
3D model (JSmol)
  • CC1=CC(=C2C(=C1C3CCNCC3)OCCO2)NC4=NC=C(C(=N4)NC5=CC=CC=C5S(=O)(=O)C(C)C)Cl
  • InChI=1S/C27H32ClN5O4S/c1-16(2)38(34,35)22-7-5-4-6-20(22)31-26-19(28)15-30-27(33-26)32-21-14-17(3)23(18-8-10-29-11-9-18)25-24(21)36-12-13-37-25/h4-7,14-16,18,29H,8-13H2,1-3H3,(H2,30,31,32,33)
  • Key:ABKQZNVWMCRCGQ-UHFFFAOYSA-N

Dirozalkib is a drug that was developed by Xuanzhu Biopharmaceutical for the treatment of non-small cell lung cancer. It is an anaplastic lymphoma kinase inhibitor.

It was approved for use in China in August of 2025.